Together with the sample analysis result that the activity score of RIPK2 is highly correlated with c-Myc activity scores in clinical tissue specimens of 32 cancer types (Yan et al., 2022), we speculate that RIPK2 could also be a potential target for HCC treatment with high reliability. Here, RIPK2 is linked to hepatocellular carcinoma.